Go To Global Site
Willkommen bei UCB Schweiz

ZILBRYSQ® is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti‑acetylcholine receptor (AChR) antibody positive.

Zilucoplan RMP Educational Materials

These essential resources contain important information to minimize the risk of meningococcal infection associated with Zilucoplan.

The patient or, if appropriate, their caregiver should be educated about treatment risks and provided with a Patient Alert Card. It is important for patients treated with Zilucoplan to always carry the Patient Alert Card with them throughout treatment and for two months after their last dose.
Please refer to the Summary of Product Characteristics for more detailed safety information about Zilucoplan.

If you have any further questions, please contact UCB-Pharma AG:
Phone: +41 (0) 58 822 31 80
E-Mail: BullePharmaMedinfo@ucb.com

IMPORTANT INFORMATION

Vaccination Confirmation

 

To minimize the risk of potential meningococcal infection with ZILBRYSQ® (Zilucoplan), ZILBRYSQ® can be dispensed only after written confirmation that the patient has received meningococcal vaccination. The supplier will not be able to process any orders for patients for whom a vaccination has not been confirmed.

Instructions on how to confirm that your patient has been vaccinated and to complete the Declaration of Vaccination are available at: https://hcp.zilucoplancap.eu/che.

Download of Zilucoplan RMP Educational Materials

German:

Information on zilucoplan and how to manage risks

Important safety information for patients and their carers

Important safety information that patients should always carry with them

Important information for dispensing pharmacists in relation to the zilucoplan controlled access program

 

French:

Information on zilucoplan and how to manage risks

Important safety information for patients and their carers

Important safety information that patients should always carry with them

Important information for dispensing pharmacists in relation to the zilucoplan controlled access program

 

Italian:

Information on zilucoplan and how to manage risks

Important safety information for patients and their carers

Important safety information that patients should always carry with them

Important information for dispensing pharmacists in relation to the zilucoplan controlled access program

Reporting of Adverse Events

Healthcare professionals should report suspected adverse reactions, especially meningococcal infections, via the ElViS portal (Electronic Vigilance System) at the following link: Reporting of adverse drug reactions for healthcare professionals (swissmedic.ch)
 

Please provide as much information as possible when reporting suspected adverse reactions, including comorbidities, past medical history, concomitant medication, and relevant timings and dates.

Alternatively, suspected side effects can be reported to UCB at: 

UCB-Pharma AG
Chem. de la Croix-Blanche 10
1630 Bulle
Switzerland
Phone: +41 (0)58 822 3180
E-Mail: 2ds.ch@ucb.com 

 

qThis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions. Healthcare Professionals should report suspected adverse reactions via the ElViS portal (Electronic Vigilance System).

 

CH-ZL-2400062, Date of preparation: January 2025

You are about to leave www.ucbsuisse.ch.

Dieser Link öffnet in einem neuen Fenster eine Webseite eines anderen Anbieters, für deren Inhalte die UCB Pharma GmbH nicht verantwortlich ist.

Yes, Continue No, Cancel

You are about to leave www.ucbsuisse.ch.

Dieser Link öffnet in einem neuen Fenster eine Webseite eines anderen Anbieters, für deren Inhalte die UCB Pharma GmbH nicht verantwortlich ist.

Yes, Continue No, Cancel

Über UCB

Nachhaltigkeit

Therapiebereiche

UCB Worldwide

 Search

Patienten

Produkte

Aktuelles

Karriere

Kontakt

You are about to leave www.ucbsuisse.ch.

Dieser Link öffnet in einem neuen Fenster eine Webseite eines anderen Anbieters, für deren Inhalte die UCB Pharma GmbH nicht verantwortlich ist.

Yes, Continue No, Cancel

© 2009 - 2022 UCB Farchim S.A., Alle Rechte vorbehalten.